New chemo combo shows promise for rare brain cancer before radiation
NCT ID NCT04755023
First seen May 13, 2026 · Last updated Jun 16, 2026 · Updated 7 times
Summary
This study tested a combination of two chemotherapy drugs, BCNU and TMZ, given before radiation therapy in 53 people newly diagnosed with a rare type of brain tumor (anaplastic oligodendroglioma or oligoastrocytoma). The goal was to see how many patients' tumors shrank with this approach. Researchers also looked at genetic markers in the tumors to help guide future treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGODENDROGLIOMA; OLIGOASTROCYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance Publique - Hôpitaux de Marseille
Marseille, 13005, France
Conditions
Explore the condition pages connected to this study.